NCT05794204View on ClinicalTrials.gov

RMP-A03 Ocular Suspension in Patients With Pterygium

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

January 12, 2024

Study Completion Date

January 12, 2024

Conditions
Pterygium
Interventions
DRUG

RMP-A03 - Dose 1

Patients will randomized to low dose of RMP-A03

DRUG

RMP-A03 - Dose 2

Patients will be randomized to high dose of RMP-A03

DRUG

RMP-A03 Placebo

Patients will be randomized to RMP-A03 Placebo

Trial Locations (6)

33144

Oceane7 Medical & Research Center Inc., Miami

37215

Toyos Clinic, Nashville

78731

Keystone Research, Austin

90301

United Medical Research Institute, Inglewood

91204

Global Research Management, Glendale

92663

Eye Research Foundation Inc, Newport Beach

All Listed Sponsors
collaborator

WuXi Clinical

INDUSTRY

lead

Suzhou Raymon Pharmaceuticals Company, Ltd.

INDUSTRY

NCT05794204 - RMP-A03 Ocular Suspension in Patients With Pterygium | Biotech Hunter | Biotech Hunter